12/04/2015 - 21:04 SAN FRANCISCO – Apremilast met its primary endpoint at week 32 with no new or serious safety signals among patients with moderate to severe plaque p... More » Visit websiteField of Interest: DermatologyCategories: SAN || Clinical NewsSAN || NewsSAN || PsoriasisRHEUM || NewsIMN || NewsIMN || DermatologyFPN || NewsNews Feed: Internal Medicine News - Dermatology